5-Bromo-3-iodo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole

Catalog No. :
ACBXYE917
CAS No. :
1012104-27-6
Molecular Formula :
C13H18BrIN2OSi
Molecular Weight :
453.19

IUPAC Name:5-bromo-3-iodo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole

5-Bromo-3-iodo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$1492.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Bromo-3-iodo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole
IUPAC Name5-bromo-3-iodo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole
Molecular FormulaC13H18BrIN2OSi
Molecular Weight453.19
SMILESC[Si](CCOCN1N=C2C=CC(Br)=CC2=C1I)(C)C
InChI KeyMDHCPIBMQLFBAX-UHFFFAOYSA-N
Synonym2H-INDAZOLE, 5-BROMO-3-IODO-2-[[2-(TRIMETHYLSILYL)ETHOXY]METHYL]-;5-Bromo-3-iodo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole;5-bromo-3-iodo-2-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole
CAS No.1012104-27-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACBXYE917 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBXYE917 route product structure diagram
    ACBXYE9171012104-27-6
Inquiry

2. ACBXYE917 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTDIA958 route compound structure diagram
    ACTDIA958459133-66-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBXYE917 route product structure diagram
    ACBXYE9171012104-27-6
Inquiry

Comments (0)